Gunderson Dettmer Advises Arcus Biosciences on Initial Public Offering

March 15, 2018Insights

Gunderson Dettmer advised Arcus Biosciences on its initial public offering of 9,200,000 shares at the price to the public of $15.00 per share for a total of $138,000,000 in aggregate gross proceeds. Corporate partner Marcia Hatch, IPOs and equity capital markets partner Richard Blake, and associates Colin Coklin and Cathy Kwon led the team advising Arcus.

The underwriting syndicate included Citigroup, Goldman Sachs & Co. and Leerink Partners. 

Arcus, which trades on the New York Stock Exchange under the ticker symbol “RCUS,” is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities.